



## Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

September 30, 2024

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Sep. 30, 2024-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene and Cell Therapies for Cancer conference, taking place October 16 – 17, 2024, in Philadelphia, PA.

Details of the oral presentation are as follows:

**Title:** ADI-270: An Armored Allogeneic Anti-CD70 CAR  $\gamma\delta$  T cell Therapy Designed for Enhanced Potency and Persistence Against Multiple Oncology Indications

**Session Name:** Novel Targets and Effector Cells

**Abstract Number:** 8

**Presenting Author:** Shon Green, Ph.D.

**Date and Time:** October 17, 2024; 11:15 a.m. – 11:30 a.m. ET

### About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at <https://www.adicetbio.com>.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240930541778/en/): <https://www.businesswire.com/news/home/20240930541778/en/>

### Adicet Bio, Inc.

#### Investors:

Anne Bowdidge

[abowdidge@adicetbio.com](mailto:abowdidge@adicetbio.com)

Janhavi Mohite

Precision AQ

212-362-1200

[janhavi.mohite@precisionaq.com](mailto:janhavi.mohite@precisionaq.com)

#### Media:

Kerry Beth Daly

[kbdaly@adicetbio.com](mailto:kbdaly@adicetbio.com)

Source: Adicet Bio, Inc.